U.S. markets closed
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.45
    +0.17 (+0.76%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.50%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.36%)
     
  • BTC-USD

    49,341.44
    +896.89 (+1.85%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Bristol Myers' TYK2 Inhibitor Disappoints In Mid-Stage Ulcerative Colitis Study

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Bristol Myers Squibb & Co (NYSE: BMY) has announced topline data from the Phase 2 LATTICE-UC study evaluating deucravacitinib in moderate to severe ulcerative colitis (UC).

  • The study did not meet the primary efficacy endpoint of clinical remission at Week 12 nor secondary efficacy endpoints.

  • The safety profile of deucravacitinib was consistent with previously reported studies in psoriasis and psoriatic arthritis, and no new safety signals were observed.

  • The Company will complete a full review of the data from LATTICE-UC.

  • The potential of deucravacitinib in UC continues to be evaluated in IM011-127, a second Phase 2 trial that includes a higher dose.

  • Bristol Myers Squibb continues to expect over $4 billion non-risk adjusted revenue target for deucravacitinib in 2029.

  • Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor.

  • Price Action: BMY stock is up 0.14% at $59.27 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.